Clinical Trial Update: Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 study of canfosfamide in refractory or relapsed mantle cell lymphoma, B-cell lymphoma, and multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma

Drugs mentioned

• Canfosfamide (canfosfamide)

Snippet

Sponsor: Telik | Conditions: Mantle Cell Lymphoma, B Cell Lymphoma | Phase 2 | Status: COMPLETED